David Wohl

The Protective and Pathologic Features of the LASV Immune Response (LASV Legacy)

National Institute of Allergy and Infectious Diseases · R01

PI · $675.3K · Univ of North Carolina Chapel Hill

The Protective and Pathologic Features of the EVD Survivor Immune System

National Institute of Allergy and Infectious Diseases · R01

PI · $2.8M · Univ of North Carolina Chapel Hill

University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit

National Institute of Allergy and Infectious Diseases · UM1

PI · $29.6M · Univ of North Carolina Chapel Hill

HIV PrEP Perspectives of Liberian Adolescent Girls and Young Women and Their Providers

National Institute of Mental Health · R21

Contact PI · $378.2K · Univ of North Carolina Chapel Hill

Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX

Principal investigator · Completed

University of North Carolina, Chapel Hill

Raltegravir as Early Therapy in African-Americans Living With HIV Study

Principal investigator · Completed · Phase 1

David A Wohl, MD

A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

Principal investigator · Completed · Phase 4

Duke University

Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

Study chair · Withdrawn · Phase 2

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections